Nucleolin-mediated cancer diagnostics and therapy

Patent metadata

Field	Value
Publication number	US-11434288-B2
Application number	US-41206509-A
Country	US
Kind code	B2
Filing date	Mar 26, 2009
Priority date	May 12, 2005
Publication date	Sep 6, 2022
Grant date	Sep 6, 2022

Abstract

The present invention provides for diagnostic kits for identifying cancer patients who are more susceptible to cancer therapies employing endostatin and other angiogenesis inhibitors, based upon the discovery that Nucleolin is a specific receptor for Endostatin. In particular, the diagnostic kits include antibody molecules against Nucleolin, DNA or RNA molecules that specifically bind to nucleic acid molecules encoding Nucleolin. The present invention also discloses methods of screening for angiogenesis inhibitors which specifically interact with Nucleolin, and act as angiogenesis inhibitors in an analogous manner as Endostatin. In addition, the present invention discloses methods of inhibiting the proliferation of endothelial cells or angiogenesis of tumor by administering an anti-nucleolin antibody linked to a cytotoxic agent such as tumor necrosis factor alpha to the endothelial cells.

First claim

We claim:

1. A method of determining the susceptibility of a subject with a tumor to endostatin therapy, comprising:
(a) performing an immunoassay on a tumor tissue sample from the subject for the presence of cell surface nucleolin on endothelial cells in tumor blood vessels;
(b) determining if the subject is susceptible to endostatin therapy based on the result of the immunoassay, wherein the presence of cell surface nucleolin on endothelial cells in tumor blood vessels of the tumor tissue sample indicates that the subject is susceptible to endostatin therapy; and
(c) administering, to the subject that is determined to be susceptible to endostatin therapy, endostatin in an amount effective to inhibit angiogenesis.

2. The method of claim 1 , wherein the immunoassay is performed with an antibody that specifically binds to nucleolin.

3. The method of claim 2 , wherein the formation of a complex between the antibody and nucleolin is detected.

4. The method of claim 2 , wherein the antibody is a monoclonal antibody.

5. The method of claim 1 , wherein the subject is a mammal.

6. The method of claim 5 , wherein the mammal is a human.

7. The method of claim 1 , wherein the endothelial cells are capillary endothelial cells.

8. The method of claim 1 , wherein the tumor blood vessels are angiogenic blood vessels.

9. The method of claim 8 , wherein the endothelial cells are proliferating endothelial cells.

10. A method of treating a subject having a tumor comprising:
(a) selecting a subject that is determined to be susceptible to endostatin therapy using the method of claim 1 ; and
(b) administering to the subject endostatin in an amount effective to inhibit angiogenesis.

11. The method of claim 10 , wherein the tumor is a cancer.

12. The method of claim 10 , wherein the subject is a mammal.

13. The method of claim 10 , wherein the subject is a human.

14. A method of determining the susceptibility of a subject with a tumor to endostatin therapy, comprising:
(a) performing an immunoassay on a tumor tissue sample from said subject to detect the presence of nucleolin on the surface of endothelial cells;
(b) identifying the subject is susceptible to endostatin therapy based on the result of the immunoassay, wherein increased level of nucleolin on the cell surface of said endothelial cells in tumor blood vessels compared to a level of nucleolin in a control sample indicates that the subject is susceptible to endostatin therapy; and
(c) administering, to the subject that is determined to be susceptible to endostatin therapy, endostatin in an amount effective to inhibit angiogenesis.

15. The method according to claim 14 , wherein the control sample is a normal heart tissue, lung tissue, or kidney tissue.

Assignees

• Luo Yongzhang
• Shi Hubing
• Protogen Ltd
• Univ Tsinghua

Inventors

• Luo Yongzhang
• Shi Hubing

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• C07K16/28 Primary

  against receptors, cell surface antigens or cell surface determinants · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• A61P35/00

  Antineoplastic agents · CPC title